drugset / Trial / NCT04240054
Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a single-arm, open-label phase II study with a safety lead-in phase.
Timeline
- Start
- 2021-11-02
- Primary completion
- 2029-12-01
- Completion
- 2030-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Isatuximab | Monoclonal antibody | 10 mg/kg | — |
| Background | Bortezomib | Small molecule | 1.5 mg/m2 | Subcutaneous |
| Background | Cyclophosphamide | Other / unclassified | 250 mg/m2 | — |
| Background | Dexamethasone | Small molecule | 10 mg | Oral |
| Background | Dexamethasone | Small molecule | 20 mg | Oral |